Focused on in patient disorders characterized by acute and chronic lung and systemic inflammation, Aqualung Therapeutics is an early stage biotech company developing immune-focused therapeutic antibodies: innovative tools are designed to prevent, diagnose and treat fluid accumulation in the lungs or pulmonary edema for inflammatory lung disorders that include acute lung injury, asthma, pulmonary hypertension, sarcoidosis, idiopathic pulmonary fibrosis and lung complications of sickle cell disease. The firm's science-driven approaches had earlier led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) and other key proteins expressed in both acute and chronic lung inflammatory diseases - all conditions representing an unnet medical need with significant morbidity and mortality.